文献速递糖尿病

比较IDegLira与基础-餐时胰岛素方案在血糖控制不佳且HbA1c极高≥9-15%的2型糖尿病患者中疗效与安全性的随机对照试验:DUAL HIGH研究

A Randomized Controlled Trial Comparing the Efficacy and Safety of IDegLira Versus Basal-Bolus in Patients With Poorly Controlled Type 2 Diabetes and Very High HbA1c ≥9-15%: DUAL HIGH Trial.
PubMed 文献 · Diabetes Care · 2023-01-01

该随机试验在HbA1c≥9.0-15.0%的2型糖尿病患者中比较IDegLira与基础-餐时胰岛素方案,主要终点为HbA1c降幅的非劣效性(0.4%)。两组HbA1c降幅无统计学显著差异,IDegLira组低血糖<70 mg/dL发生率更低、体重增加更少。

要点

  • 在HbA1c≥9.0-15.0%的2型糖尿病患者中,IDegLira与基础-餐时胰岛素方案的HbA1c降幅无统计学显著差异。
  • IDegLira组低血糖<70 mg/dL发生率显著低于基础-餐时组(26% vs 48%,P=0.008)。
  • IDegLira组体重增加显著少于基础-餐时组(1.24±8.33 vs 5.84±6.18 kg,P=0.001)。

核心结论

  • 在HbA1c≥9.0-15.0%的2型糖尿病患者中,与基础-餐时胰岛素方案相比,IDegLira的HbA1c降幅相似、低血糖更少且体重增加更少。

研究设计与样本

  • 随机对照试验,纳入既往接受2或3种口服药和/或基础胰岛素治疗、HbA1c≥9.0-15.0%的2型糖尿病患者,按1:1分配至基础-餐时组(n=73)或IDegLira组(n=72)。
  • 主要终点为两组间HbA1c降幅的非劣效性(界值0.4%)。

主要发现

  • 145例参与者基线HbA1c为10.8%±1.3,IDegLira组与基础-餐时组HbA1c降幅分别为3.18%±2.29与3.00%±1.79,差异无统计学显著(P=0.65;估计治疗差异ETD 0.18%,95%CI -0.59至0.94)。
  • IDegLira组低血糖<70 mg/dL发生率显著低于基础-餐时组(26% vs 48%,P=0.008;比值比OR 0.39,95%CI 0.19至0.78)。
  • IDegLira组体重增加显著少于基础-餐时组(1.24±8.33 kg vs 5.84±6.18 kg,P=0.001;ETD -4.60,95%CI -7.33至-1.87)。

关键数值与推荐

  • 基线HbA1c>9.0-10.0%的2型糖尿病患者,指南推荐基础-餐时胰岛素治疗。
  • 主要终点非劣效性界值为HbA1c降幅0.4%。
  • 低血糖<70 mg/dL:IDegLira组26% vs 基础-餐时组48%,P=0.008,OR 0.39(95%CI 0.19至0.78)。
  • 体重增加:IDegLira组1.24±8.33 kg vs 基础-餐时组5.84±6.18 kg,P=0.001,ETD -4.60(95%CI -7.33至-1.87)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In participants with type 2 diabetes (T2D) and HbA1c >9.0-10.0%, guidelines recommend treatment with basal-bolus insulin. RESEARCH DESIGN AND METHODS: This randomized trial compared the efficacy and safety of insulin degludec and liraglutide (IDegLira) and basal-bolus among participants with high HbA1c ≥9.0-15.0%, previously treated with 2 or 3 oral agents and/or basal insulin, allocated (1:1) to basal-bolus (n = 73) or IDegLira (n = 72). The primary end point was noninferiority (0.4%) in HbA1c reduction between groups. RESULTS: Among 145 participants (HbA1c 10.8% ± 1.3), there was no statistically significant difference in HbA1c reduction (3.18% ± 2.29 vs. 3.00% ± 1.79, P = 0.65; estimated treatment difference (ETD) 0.18%, 95% CI -0.59, 0.94) between the IDegLira and basal-bolus groups. IDegLira resulted in significantly lower rates of hypoglycemia <70 mg/dL (26% vs. 48%, P = 0.008; odds ratio 0.39, 95% CI 0.19, 0.78), and less weight gain (1.24 ± 8.33 vs. 5.84 ± 6.18 kg, P = 0.001; ETD -4.60, 95% CI -7.33, -1.87). CONCLUSIONS: In participants with T2D and HbA1c ≥9.0-15.0%, IDegLira resulted in similar HbA1c reduction, less hypoglycemia, and less weight gain compared with the basal-bolus regimen.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Galindo RJ, Moazzami B, Scioscia MF, et al. A Randomized Controlled Trial Comparing the Efficacy and Safety of IDegLira Versus Basal-Bolus in Patients With Poorly Controlled Type 2 Diabetes and Very High HbA1c ≥9-15%: DUAL HIGH Trial. Diabetes Care. 2023. PMID: 37459574. doi:10.2337/dc22-2426

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。